Premium
Genetic alteration and immunohistochemical staining patterns of ovarian high‐grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern
Author(s) -
Lee Sang Hwa,
Kim Hyunkyung,
Kim Wook Youn,
Han Hye Seung,
Lim So Dug,
Kim Wan Seop,
Kim Sehun,
Hwang Tae Sook
Publication year - 2013
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.12060
Subject(s) - frameshift mutation , immunostaining , missense mutation , kras , nonsense mutation , serous fluid , pathology , immunohistochemistry , cancer research , nonsense , biology , adenocarcinoma , mutation , medicine , cancer , genetics , gene
We evaluated p53, KRAS , BRAF and CTNNB 1 mutation and p53, WT 1, p16 and beta‐catenin expression in 31 ovarian high‐grade serous adenocarcinoma. Twenty‐five (80.6%) tumors contained functional mutations of p53 ; three frameshift, four nonsense and 19 missense mutations. None of the tumors showed KRAS , BRAF or CTNNB 1 mutation. In all 18 tumors with missense mutations, ≥60% of tumor cells were strongly positive for p53 immunostaining whereas all tumors with frameshift or nonsense mutations were completely negative. Missense mutation was correlated with diffuse and strong imunoreaction and frameshift/nonsense mutation was correlated with completely negative immunoreaction ( P = 0.000). Tumors with wild‐type p53 revealed a wide range of immunostaining patterns. In 27 (87.1%) and 18 (58.1%) tumors, ≥50% of tumor cells were moderate to strongly positive for WT 1 and p16, respectively. A considerable intratumoral heterogeneity for p16 expression was present. None of the tumors demonstrated nuclear beta‐catenin expression. p53 mutations appear to be a powerful molecular marker for ovarian high‐grade serous adenocarcinoma. Using p53 with an appropriate interpretation criteria together with WT 1, p16 and beta‐catenin, most of the high‐grade serous adenocarcinoma could be distinguished from other ovarian tumors.